CVS Health plans to separate its retail pharmacy business, including roughly 9,000 retail locations, from its insurance arm Aetna and pharmacy benefit manager Caremark, with the new structure expected by the first half of 2028. After walking away from a breakup idea more than two years ago, the company now argues it is doing this from strength rather than distress. That framing deserves to be taken seriously, because the business that stood on its own was not the same one analysts questioned back then.
The evidence in the report supports at least part of that case. CVS has posted eight consecutive quarters of beating Wall Street earnings estimates, has raised guidance several times, and expects at least $15.5 billion in operating cash flow in 2026, up from $9.1 billion in 2024. Analysts such as Michael Cherny at Leerink Partners point to a pharmacy segment that has become more stable, helped by competitors like Walgreens and Rite Aid retreating and by the CostVantage reimbursement model. Joyner's claim that the company can now make this choice without any distress is credible on those numbers.
Still, a stable pharmacy is not a high-growth one. The report notes that the retail segment's adjusted operating margins sit at roughly 4% to 5%, and that investors value it at a discount. Separating a low-margin unit may unlock clarity for the insurer and PBM, but it also risks leaving the retail arm with less bargaining power and a thinner balance sheet. Investors who sent shares down about 12% on the announcement appear to share that doubt, and they are not wrong to question whether the pieces will be worth more apart.
The regulatory backdrop cannot be waved away either. Caremark faces state laws in Tennessee and Arkansas aimed at separating pharmacies from PBMs, and Cherny has described a steady stream of state lawsuits. Joyner has said regulation is not the reason for the split, and CVS deserves to be judged on its stated strategy. But the company should expect that the next few years will test whether a standalone structure makes compliance easier or simply moves the pressure to a different address.
My view is that the split is a sensible bet, provided CVS treats the separation as a test of discipline rather than a victory lap. The company should publish clear terms for how the two businesses will continue to work together, and it should show that patients and pharmacies are not worse off. If the retail unit can hold its margins and the insurer keeps its medical-cost gains, the move will look wise by 2028. If not, the breakup will have simply divided the problems.